Simon Faissner

1.9k total citations · 1 hit paper
61 papers, 1.3k citations indexed

About

Simon Faissner is a scholar working on Neurology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Simon Faissner has authored 61 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Neurology, 27 papers in Pathology and Forensic Medicine and 12 papers in Oncology. Recurrent topics in Simon Faissner's work include Multiple Sclerosis Research Studies (27 papers), Peripheral Neuropathies and Disorders (15 papers) and Neuroinflammation and Neurodegeneration Mechanisms (8 papers). Simon Faissner is often cited by papers focused on Multiple Sclerosis Research Studies (27 papers), Peripheral Neuropathies and Disorders (15 papers) and Neuroinflammation and Neurodegeneration Mechanisms (8 papers). Simon Faissner collaborates with scholars based in Germany, United States and Canada. Simon Faissner's co-authors include Ralf Gold, V. Wee Yong, Jason R. Plemel, Andrew Chan, Robert Hoepner, Björn Ambrosius, Aiden Haghikia, Christos Krogias, Anke Salmen and Steffen Haupeltshofer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Simon Faissner

57 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

2019 308 citations Simon Faissner, Jason R. Plemel et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by Simon Faissner

Since Specialization

Citations

This map shows the geographic impact of Simon Faissner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Faissner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Faissner more than expected).

Fields of papers citing papers by Simon Faissner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Faissner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Faissner. The network helps show where Simon Faissner may publish in the future.

Co-authorship network of co-authors of Simon Faissner

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Faissner. A scholar is included among the top collaborators of Simon Faissner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Faissner. Simon Faissner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Anti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis 2025 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), Athina‐Maria Aloizou, Christoph H. Lohmann, Simon Faissner, (unknown), Dominic Borie, Thomas Mika, Roland Schroers, Jeremias Motte, Ralf Gold	1
2	Chimeric antigen receptor T-cell therapy for stiff-person syndrome: bridging innovation and clinical challenges in neuroimmunology 2025 ·Therapeutic Advances in Neurological Disorders ·Jonathan Wickel, Jeremias Motte, Ilya Ayzenberg, (unknown), Ralf Gold, Christian Geis, Simon Faissner	0
3	Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series 2025 ·Frontiers in Immunology ·Regina Berkovich, Jonathan Calkwood, Heidi Crayton, (unknown), Simon Faissner, Ralf Gold, (unknown), (unknown)	1
4	Eomesodermin-expressing CD4+ Th cells and association with pregnancy in multiple sclerosis 2024 ·Therapeutic Advances in Neurological Disorders ·Simon Faissner, (unknown), (unknown), Sandra Thiel, Takashi Yamamura, Kerstin Hellwig, Ralf Gold	0
5	Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models 2024 ·Scientific Reports ·(unknown), (unknown), (unknown), (unknown), Seray Demir, (unknown), Ralf Gold, Simon Faissner	2
6	Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome 2024 ·Proceedings of the National Academy of Sciences ·Simon Faissner, Jeremias Motte, (unknown), Christian Geis, Aiden Haghikia, Dimitrios Mougiakakos, Dominic Borie, Roland Schroers, Ralf Gold	25
7	Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials 2023 ·Therapeutic Advances in Neurological Disorders ·Antonios Bayas, Monika Christ, Simon Faissner, Juliane Klehmet, Refik Pul, Thomas Skripuletz, Sven G. Meuth	14
8	Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments 2022 ·CNS Drugs ·Simon Faissner, Ralf Gold	21
9	Hypoechogenicity of brainstem raphe in long-COVID syndrome–less common but independently associated with depressive symptoms: a cross-sectional study 2022 ·Journal of Neurology ·Daniel Richter, (unknown), (unknown), (unknown), (unknown), Ralf Gold, Christos Krogias, Simon Faissner	8
10	Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort 2022 ·Therapeutic Advances in Neurological Disorders ·(unknown), Carsten Saft, Simon Faissner, Gisa Ellrichmann	3
11	Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination 2022 ·Therapeutic Advances in Neurological Disorders ·Simon Faissner, (unknown), (unknown), (unknown), (unknown), Carlos Plaza‐Sirvent, (unknown), (unknown), Ilya Ayzenberg, Kerstin Hellwig, Ingo Schmitz, Stephanie Pfaender, Ralf Gold	3
12	Cross-sectional analysis of clinical aspects in patients with long-COVID and post-COVID syndrome 2022 ·Frontiers in Neurology ·(unknown), (unknown), (unknown), Daniel Richter, Thivya Pakeerathan, (unknown), Ilya Ayzenberg, Ralf Gold, Simon Faissner	7
13	Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV 2022 ·Frontiers in Immunology ·(unknown), Carlos Plaza‐Sirvent, (unknown), Jaydeep Bhat, (unknown), Doris Urlaub, (unknown), (unknown), (unknown), (unknown), Adriane Skaletz‐Rorowski, Norbert H. Brockmeyer, (unknown), Anke Reinacher‐Schick, Simon Faissner, Carsten Watzl, Stephanie Pfaender, Anja Potthoff, Ingo Schmitz	11
14	Progressive Retinal and Optic Nerve Damage in a Mouse Model of Spontaneous Opticospinal Encephalomyelitis 2022 ·Frontiers in Immunology ·(unknown), Sabrina Reinehr, Steffen Haupeltshofer, (unknown), (unknown), Ingo Kleiter, H. Burkhard Dick, Ralf Gold, Simon Faissner, Stephanie C. Joachim	7
15	Contemplating Dichotomous Nature of Gamma Delta T Cells for Immunotherapy 2022 ·Frontiers in Immunology ·Jaydeep Bhat, Katarzyna Placek, Simon Faissner	10
16	The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany 2021 ·Therapeutic Advances in Neurological Disorders ·Daniel Richter, Simon Faissner, Dirk Bartig, Lars Tönges, Kerstin Hellwig, Ilya Ayzenberg, Christos Krogias, Ralf Gold	7
17	Endocarditis following ocrelizumab in relapsing-remitting MS 2020 ·Neurology Neuroimmunology & Neuroinflammation ·Simon Faissner, Michael Schwake, Michael Gotzmann, Andreas Mügge, Stephan Schmidt, Ralf Gold	6
18	Progressive multiple sclerosis: from pathophysiology to therapeutic strategies breakdown → 2019 ·Nature Reviews Drug Discovery ·Simon Faissner, Jason R. Plemel, Ralf Gold, V. Wee Yong	308
19	Progressive multiple sclerosis: latest therapeutic developments and future directions 2019 ·Therapeutic Advances in Neurological Disorders ·Simon Faissner, Ralf Gold	51
20	Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010 2018 ·CNS Drugs ·Simon Faissner, Ralf Gold	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact